Statins in relation to adiponectin: A significant association with clinical implications

Atherosclerosis

Volumn 253, Issue , 2016, Pages 270-272

  Katsiki, Niki ^a   Mantzoros, Christos S ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Cardiovascular risk; New onset diabetes; Pleiotropic effects; Statins

Indexed keywords

ADIPONECTIN; ATORVASTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFECT; EDITORIAL; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; LIPID METABOLISM; META ANALYSIS (TOPIC); OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); RISK FACTOR;

ADIPONECTIN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 84991691524     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.08.009     Document Type: Editorial

References (57)

1. [1] Chruściel, P., Sahebkar, A., Rembek, M., Serban, M.C., Ursoniu, S., Mikhailidis, D.P., Jones, S.R., Mosteoru, S., Blaha, M.J., Martin, S.S., Rysz, J., Toth, P.P., Lip, G.Y.H., Pencina, M.J., Ray, K.K., Banach, M., Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016 In press.
2. [2] Chapman, M.J., Orsoni, A., Robillard, P., Hounslow, N., Sponseller, C.A., Giral, P., Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr. Med. Res. Opin. 30:5 (2014), 775–784.
3. [3] Barrios, V., Escobar, C., Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes. Future Cardiol. 12:4 (2016), 449–466.
4. [4] Cho, Y., Choe, E., Lee, Y.H., Seo, J.W., Choi, Y., Yun, Y., Wang, H.J., Ahn, C.W., Cha, B.S., Lee, H.C., Kang, E.S., Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 64:4 (2015), 482–488.
5. [5] Comninos, A.N., Jayasena, C.N., Dhillo, W.S., The relationship between gut and adipose hormones, and reproduction. Hum. Reprod. Update 20:2 (2014), 153–174.
6. [6] Lim, S., Quon, M.J., Koh, K.K., Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 233:2 (2014), 721–728.
7. [7] Villarreal-Molina, M.T., Antuna-Puente, B., Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 94:10 (2012), 2143–2149.
8. [8] Matsuda, M., Shimomura, I., Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev. Endocr. Metab. Disord. 15:1 (2014), 1–10.
9. [9] Ebrahimi-Mamaeghani, M., Mohammadi, S., Arefhosseini, S.R., Fallah, P., Bazi, Z., Adiponectin as a potential biomarker of vascular disease. Vasc. Health Risk Manag. 11 (2015), 55–70.
10. [10] Rojas, E., Rodríguez-Molina, D., Bolli, P., Israili, Z.H., Faría, J., Fidilio, E., Bermúdez, V., Velasco, M., The role of adiponectin in endothelial dysfunction and hypertension. Curr. Hypertens. Rep., 16(8), 2014, 463.
11. [11] Caselli, C., D'Amico, A., Cabiati, M., Prescimone, T., Del Ry, S., Giannessi, D., Back to the heart: the protective role of adiponectin. Pharmacol. Res. 82 (2014), 9–20.
12. [12] Dalamaga, M., Diakopoulos, K.N., Mantzoros, C.S., The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 33:4 (2012), 547–594.
13. [13] Bigalke, B., Stellos, K., Geisler, T., Seizer, P., Mozes, V., Gawaz, M., High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets 21:1 (2010), 11–19.
14. [14] Kato, H., Kashiwagi, H., Shiraga, M., Tadokoro, S., Kamae, T., Ujiie, H., Honda, S., Miyata, S., Ijiri, Y., Yamamoto, J., Maeda, N., Funahashi, T., Kurata, Y., Shimomura, I., Tomiyama, Y., Kanakura, Y., Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol. 26:1 (2006), 224–230.
15. [15] Blüher, M., Mantzoros, C.S., From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 64:1 (2015), 131–145.
16. [16] Menzaghi, C., Trischitta, V., Doria, A., Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 56:5 (2007), 1198–1209.
17. [17] Gulcelik, N.E., Halil, M., Ariogul, S., Usman, A., Adipocytokines and aging: adiponectin and leptin. Minerva Endocrinol. 38:2 (2013), 203–210.
18. [18] Forouhi, N.G., Sattar, N., CVD risk factors and ethnicity–a homogeneous relationship?. Atheroscler. Suppl. 7:1 (2006), 11–19.
19. [19] von Frankenberg, A.D., Silva, F.M., de Almeida, J.C., Piccoli, V., do Nascimento, F.V., Sost, M.M., Leitão, C.B., Remonti, L.L., Umpierre, D., Reis, A.F., Canani, L.H., de Azevedo, M.J., Gerchman, F., Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials. Br. J. Nutr. 112:8 (2014), 1235–1250.
20. [20] Schwingshackl, L., Hoffmann, G., Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. Nutr. Metab. Cardiovasc Dis. 24:9 (2014), 929–939.
21. [21] Lee, S., Kwak, H.B., Effects of interventions on adiponectin and adiponectin receptors. J. Exerc Rehabil. 10:2 (2014), 60–68.
22. [22] Belalcazar, L.M., Lang, W., Haffner, S.M., Schwenke, D.C., Kriska, A., Balasubramanyam, A., Hoogeveen, R.C., Pi-Sunyer, F.X., Tracy, R.P., Ballantyne, C.M., Look, A.H.E.A.D., (Action for health in diabetes) research group. Improving adiponectin levels in individuals with diabetes and obesity: insights from Look AHEAD. Diabetes Care 38:8 (2015), 1544–1550.
23. [23] Kishida, K., Funahashi, T., Shimomura, I., Adiponectin as a routine clinical biomarker. Best. Pract. Res. Clin. Endocrinol. Metab. 28:1 (2014), 119–130.
24. [24] Sweiss, N., Sharma, K., Adiponectin effects on the kidney. Best. Pract. Res. Clin. Endocrinol. Metab. 28:1 (2014), 71–79.
25. [25] Jia, T., Carrero, J.J., Lindholm, B., Stenvinkel, P., The complex role of adiponectin in chronic kidney disease. Biochimie 94:10 (2012), 2150–2156.
26. [26] Wanders, D., Plaisance, E.P., Judd, R.L., Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J. Diabetes 1:4 (2010), 116–128.
27. [27] Koh, K.K., Oh, P.C., Sakuma, I., Kim, E.Y., Lee, Y., Hayashi, T., Han, S.H., Park, Y.M., Shin, E.K., Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int. J. Cardiol. 199 (2015), 126–131.
28. [28] Katsiki, N., Theocharidou, E., Karagiannis, A., Athyros, V.G., Mikhailidis, D.P., Ezetimibe therapy for dyslipidemia: an update. Curr. Pharm. Des. 19:17 (2013), 3107–3114.
29. [29] Sahebkar, A., Ponzo, V., Bo, S., Effect of dipeptidyl Peptidase-4 inhibitors on plasma adiponectin: a systematic review and meta-analysis of randomized controlled trials. Curr. Med. Chem. 23:13 (2016), 1356–1369.
30. [30] Omoto, S., Taniura, T., Nishizawa, T., Tamaki, T., Shouzu, A., Nomura, S., Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 8 (2015), 339–345.
31. [31] Okamoto, A., Yokokawa, H., Sanada, H., Naito, T., Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R. D., 2016 Jun 22 [Epub ahead of print].
32. [32] Li, D., Xu, X., Zhang, Y., Zhu, J., Ye, L., Lee, K.O., Ma, J., Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes. Diabetes Res. Clin. Pract. 110:2 (2015), 224–228.
33. [33] Fan, H., Pan, Q., Xu, Y., Yang, X., Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq. Bras. Endocrinol. Metabol. 57:9 (2013), 702–708.
34. [34] Katsiki, N., Mikhailidis, D.P., Gotzamani-Psarrakou, A., Yovos, J.G., Karamitsos, D., Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin. Ther. Targets 15:4 (2011), 401–420.
35. [35] Profumo, E., Buttari, B., Saso, L., Rigano, R., Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin. Curr. Top. Med. Chem. 14:22 (2014), 2542–2551.
36. [36] Satoh, M., Takahashi, Y., Tabuchi, T., Minami, Y., Tamada, M., Takahashi, K., Itoh, T., Morino, Y., Nakamura, M., Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Clin. Sci. Lond 129:2 (2015), 93–105.
37. [37] Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr. Med. Res. Opin. 31:2 (2015), 191–195.
38. [38] Athyros, V.G., Katsiki, N., Karagiannis, A., Radak, D., Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy. Curr. Vasc. Pharmacol. 13:2 (2015), 223–225.
39. [39] Katsiki, N., Athyros, V.G., Mikhailidis, D.P., Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. Atherosclerosis 238:2 (2015), 182–184.
40. [40] Côté-Daigneault, J., Mehandru, S., Ungaro, R., Atreja, A., Colombel, J.F., Potential immunomodulatory effects of statins in inflammatory bowel disease. Inflamm. Bowel Dis. 22:3 (2016), 724–732.
41. [41] Kostis, J.B., Dobrzynski, J.M., The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J. Sex. Med. 11:7 (2014), 1626–1635.
42. [42] Nikolic, D., Banach, M., Nikfar, S., Salari, P., Mikhailidis, D.P., Toth, P.P., Abdollahi, M., Ray, K.K., Pencina, M.J., Malyszko, J., Rysz, J., Rizzo, M., Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. Int. J. Cardiol. 168:6 (2013), 5437–5447.
43. [43] Katsiki, N., Mikhailidis, D.P., Mantzoros, C.S., Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65:8 (2016), 1109–1123.
44. [44] Gizzo, S., Quaranta, M., Nardelli, G.B., Noventa, M., Lipophilic statins as anticancer agents: molecular targeted actions and proposal in advanced gynaecological malignancies. Curr. Drug Targets 16:10 (2015), 1142–1159.
45. [45] Stryjkowska-Góra, A., Karczmarek-Borowska, B., Góra, T., Krawczak, K., Statins and cancers. Contemp. Oncol. Pozn. 19:3 (2015), 167–175.
46. [46] Barb, D., Williams, C.J., Neuwirth, A.K., Mantzoros, C.S., Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am. J. Clin. Nutr. 86:3 (2007), s858–s866.
47. [47] Inamura, K., Song, M., Jung, S., Nishihara, R., Yamauchi, M., Lochhead, P., Qian, Z.R., Kim, S.A., Mima, K., Sukawa, Y., Masuda, A., Imamura, Y., Zhang, X., Pollak, M.N., Mantzoros, C.S., Harris, C.C., Giovannucci, E., Fuchs, C.S., Cho, E., Chan, A.T., Wu, K., Ogino, S., Prediagnosis plasma adiponectin in relation to colorectal Cancer risk according to KRAS mutation status. J. Natl. Cancer Inst., 108(4), 2015.
48. [48] Katsiki, N., Rizzo, M., Mikhailidis, D.P., Mantzoros, C.S., New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. Metabolism 64:4 (2015), 471–475.
49. [49] Banach, M., Malodobra-Mazur, M., Gluba, A., Katsiki, N., Rysz, J., Dobrzyn, A., Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr. Pharm. Des. 19:27 (2013), 4904–4912.
50. [50] Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., Daskalopoulou, S.S., Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63:6 (2014), 735–745.
51. [51] Vallejo-Vaz, A.J., Kondapally Seshasai, S.R., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., Tsimikas, S., Yoshida, H., Ray, K.K., Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241:2 (2015), 409–418.
52. [52] Arnaboldi, L., Corsini, A., Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler. Suppl. 16 (2015), 1–27.
53. [53] Polyzos, S.A., Mantzoros, C.S., Adiponectin as a target for the treatment of nonalcoholic steatohepatitis: a systematic review. Metabolism, 2016 In press.
54. [54] Meyer, L.K., Ciaraldi, T.P., Henry, R.R., Wittgrove, A.C., Phillips, S.A., Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte 2:4 (2013), 217–226.
55. [55] Kishida, K., Funahashi, T., Shimomura, I., Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr. Metab. Immune Disord. Drug Targets 12:2 (2012), 118–131.
56. [56] Krysiak, R., Labuzek, K., Okopień, B., Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol. Rep. 61:6 (2009), 1134–1145.
57. [57] Aguirre, L., Hijona, E., Macarulla, M.T., Gracia, A., Larrechi, I., Bujanda, L., Hijona, L., Portillo, M.P., Several statins increase body and liver fat accumulation in a model of metabolic syndrome. J. Physiol. Pharmacol. 64:3 (2013), 281–288.